Login
Login

Laboratoires Servier

{{Short description|International pharmaceutical company governed by a non-profit foundation}}

{{About|the pharmaceutical company||Servier (disambiguation)}}

{{Infobox company

| name = Servier

| logo = Servier company logo.svg

| logo_size = 260px

| type = Private

| founder = Jacques Servier

| foundation = ({{start date and age|1954}})

| location_city = Suresnes, Île-de-France

| location_country = France

| location =

| key_people =

| industry = Pharmaceutical

| products = Pharmaceuticals

| revenue = {{increase}} €5.9 billion (2024)

| operating_income =

| net_income = {{increase}} €404 million (2024)

| aum =

| assets =

| equity =

| num_employees = 22,000

| homepage = {{Official website|https://servier.com/en/}}

| footnotes = {{cite web |url=http://www.servier.com/Key-Figures |title=Key figures |publisher=Servier |access-date=2015-02-03 |archive-date=2014-10-09 |archive-url=https://web.archive.org/web/20141009022333/http://www.servier.com/Key-Figures |url-status=dead }}{{cite web |url=http://www.servier.com/content/history |title=History |publisher=Servier |access-date=2015-02-03 |archive-date=2017-08-05 |archive-url=https://web.archive.org/web/20170805023547/http://www.servier.com/content/history |url-status=dead }}

}}

Servier Laboratories (French: Laboratoires Servier, often abbreviated to Servier) is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes).{{Cite web|url=https://www.bostonglobe.com/business/2019/05/09/french-drug-maker-servier-sets-headquarters-seaport/Glo5PAPGpHhTNXZiagNTJL/story.html|title=French drug maker Servier sets up US headquarters in Seaport|date=May 9, 2019|website=Boston Globe}}

The consolidated turnover for the 2018 financial year was €4.2 billion.{{Cite web|url=https://www.bizjournals.com/boston/news/2019/05/09/servier-launches-u-s-cancer-business-with-plans-to.html|title=Servier launches U.S. cancer business with plans to double headcount in next 5 years|date=May 9, 2019|website=Boston Business Journal}} Servier is the leading French independent pharmaceutical company, and the second largest French pharmaceutical company. It has branches in 149 countries, achieving 82% of its sales outside France.{{cite web|url=http://www.servier.com/|title=SERVIER - Pharmaceutical company specialized in cardiology, diabetes, rheumatology, depression|access-date=2007-07-08}}{{Cite web|url=https://www.bloomberg.com/press-releases/2019-06-11/servier-and-galapagos-complete-enrollment-of-global-roccella-phase-2-clinical-trial-with-glpg1972-s201086-in-knee-osteoarthritis|title=Servier and Galapagos complete enrollment of global ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis|date=June 11, 2019|website=Bloomberg}} The company reportedly invests a little under 25% of its turnover in research and development, which occupies 3,000 of its 22,000 employees worldwide.{{Cite web|url=https://www.biopharmadive.com/news/serviers-us-boston-headquarters-strategic-plan/554384/|title=Servier's US push takes shape as Boston HQ opens|date=May 9, 2019|website=BioPharma Dive}} The company's production sites produced 853 million drug boxes in 2013.

The Servier Clinical Support Unit in Gidy (near Orléans), which produces drugs for clinical trials, is the largest unit of its kind in Europe.{{cite web|url=http://www.servier.co.uk/aboutus/figures.asp |title=Servier UK - Key figures |access-date=2007-07-08 |url-status=dead |archive-url=https://web.archive.org/web/20070708070741/http://www.servier.co.uk/aboutus/figures.asp |archive-date=2007-07-08 }} Servier Laboratories is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).{{cite news|url=http://www.efpia.eu/content/default.asp?PageID=559&DocID=4883 |title=The Pharmaceutical Industry in Figures - 2008 Edition |publisher=European Federation of Pharmaceutical Industries and Associations (EFPIA) |page=49 |access-date=2008-08-25 |url-status=dead |archive-url=https://web.archive.org/web/20080916100937/http://www.efpia.eu/content/default.asp?PageID=559&DocID=4883 |archive-date=2008-09-16 }}

In 2018, Servier finalized the acquisition of Shire’s oncology branch in Boston and named David K. Lee as CEO. The official opening of Servier's new U.S. headquarters took place in 2019.

In 2009, Mediator, an amphetamine-based Servier drug originally developed for weight loss in people with diabetes but often prescribed off-label as a dieting aid, was withdrawn from the market after being linked to 500–2000 deaths in France.[http://www.lefigaro.fr/sante/2010/10/13/01004-20101013ARTFIG00557-le-mediator-serait-responsable-de-500-a-1000-deces-en-france.php Article of the Figaro about Mediator][http://www.liberation.fr/societe/01012310194-un-rapport-de-1998-alertait-deja-sur-le-mediator Un doute sur la «sécurité» du Mediator dès 1998 - Libération] Further investigations found that many previous safety alerts on that drug had been either missed or covered up, possibly due to the improper influence of the well-connected company. On March 29, 2021, a French court fined Servier €2.7m (£2.3m) after finding it guilty of deception and manslaughter, with Mediator linked to the deaths of up to 2,000 people. The former executive Jean-Philippe Seta was sentenced to a suspended jail sentence of four years, while the elderly Jacques Servier had died and therefore could not be sentenced. The French medicines agency, accused of failing to act quickly enough on warnings about the drug, was fined €303,000.

{{Cite web|url=https://www.theguardian.com/world/2021/mar/29/french-pharma-firm-found-guilty-over-medical-scandal-in-which-up-to-2000-died|title=French pharma firm found guilty over medical scandal in which up to 2,000 died|website=TheGuardian.com|date=29 March 2021}}

Product portfolio

Notable products:

Other products:

Collaborative research

As well as internal research and development activities, Servier undertakes publicly funded collaborative research projects with industrial and academic partners. One example, in the area of non-clinical safety assessment, is the InnoMed PredTox.{{Cite book| last1 = Mattes | first1 = William B.| chapter = Public Consortium Efforts in Toxicogenomics | doi = 10.1007/978-1-60327-048-9_11 | title = Essential Concepts in Toxicogenomics| editor1-last = Mendrick | editor1-first = Donna L.| editor2-last = Mattes | editor2-first = William B.| series = Methods in Molecular Biology| volume = 460 | pages = 221–238 | year = 2008 | isbn = 978-1-58829-638-2 | pmid = 18449490 }}{{cite web|url=http://www.innomed-predtox.com/consortium/members/ |title=InnoMed PredTox Member Organizations |access-date=2008-08-25 |url-status=dead |archive-url= https://web.archive.org/web/20080926214522/http://www.innomed-predtox.com/consortium/members/ |archive-date=2008-09-26 }} The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.{{cite web|url=http://imi.europa.eu/docs/calls01_en.zip |title=IMI Call Topics 2008|last=Innovative Medicines Initiative|work=IMI-GB-018v2-24042008-CallTopics.pdf |publisher=European Commission|access-date=2008-08-25|archive-url= https://web.archive.org/web/20091015122459/http://imi.europa.eu/docs/calls01_en.zip |archive-date=2009-10-15|url-status=dead}}

In addition to these, Servier engages in research and licensing collaborations across the pharmaceutical and biotechnology industry. These collaborations include:

  • In Cardiology: XENTION (UK, 2013), AMGEN (USA, 2013), MIRAGEN (USA, 2011), ARMGO (USA, 2006)
  • In Diabetes: INTARCIA (USA, 2014)
  • In Metabolic diseases: INTERCEPT - TGR5 agonists (USA, 2011), Genfit (FR, 2004)
  • In Neurology (MS): GENEURO (CH, 2014)
  • In Oncology: CTI BIOPHARMA (USA, 2014), NOVARTIS (CH, 2014), CELLECTIS (FR, 2014), NERVIANO (IT, 2013), EOS (IT) / CLOVIS (USA, 2012), BIOINVENT (SE, 2012), MACROGENICS (USA, 2011/12), GALAPAGOS (NDL, 2011), BIOREALITES (FR, 2011), PHARMACYCLICS - HDAC inhibitor (USA, 2009), HYBRIGENICS (FR, 2007/2011) VERNALIS (UK, 2007/2011)
  • In Orphan Diseases/Cardiology/Diabetes: XOMA (USA, 2010)
  • In Osteoporosis & Osteoarthritis: OSTEOLOGIX (USA, 2010), GALAPAGOS (NDL, 2010), KAROS (USA, 2010), NORDIC BIOSCIENCE (DK, 2006/2010)

Servier acquired Symphogen in 2020.{{cite press release |last1=A/S |first1=Symphogen |title=Servier signed a definitive agreement to acquire Symphogen, a leading antibody discovery company, to boost its antibody capabilities and leverage its R&D pipeline |url=https://www.globenewswire.com/news-release/2020/04/03/2011520/0/en/Servier-signed-a-definitive-agreement-to-acquire-Symphogen-a-leading-antibody-discovery-company-to-boost-its-antibody-capabilities-and-leverage-its-R-D-pipeline.html |website=GlobeNewswire News Room |date=3 April 2020 }}

Controversy

Servier Laboratories has been the subject of worldwide scandal for creating and distributing a weight-loss drug called Mediator (Benfluorex), which may have killed up to 2,100 people.{{Cite news|last=Samuel|first=Henry|url=https://www.telegraph.co.uk/news/2019/09/23/trial-opens-france-weight-loss-drug-killed-hundreds/|title=Trial opens in France over weight loss drug that 'killed hundreds'|date=2019-09-23|work=The Telegraph|access-date=2020-04-03|language=en-GB|issn=0307-1235}}

The movie 150 Milligrams, by director Emmanuelle Bercot, features Dr. Irène Frachon discovering that Mediator pills cause heart valve problems/deaths and how in 2009 she starts an uphill battle against the producer and the French health authorities.

In March 2021, Servier was sentenced to a fine of 2.7 million euros for aggravated deception and involuntary manslaughter, however it was acquitted of fraud charges. The court also ordered the company to pay several hundred million euros in damages to the 6,500 plaintiffs, and one of its leading managers was sentenced to four years on probation. The French medical agency ANSM was fined 300,000 euros for failing proper supervision.Nicolaus Vaux-Montagny, Francois Mori:[https://www.houstonchronicle.com/news/article/French-pharma-firm-faces-verdict-for-deadly-diet-16060023.php Paris court convicts, fines pharma firm for deadly diet pill]. Houston Chronicle (AP story), 29 March 2021[https://www.aljazeera.com/news/2021/3/29/french-court-convicts-fines-pharma-firm-for-deadly-diet-pill French company convicted of manslaughter over deadly diet pill]. Al Jazeera English, 29 March 2021[https://www.bbc.com/news/world-europe-56562909 Mediator drug: French pharmaceutical firm fined over weight loss pill]. BBC, 29 March 2021

A French pharmaceutical company, continued its operations in Russia despite international sanctions and the geopolitical consequences of Russia's invasion of Ukraine.{{Cite web |title=Servier Laboratories - Leave Russia |url=https://leave-russia.org/uk/servier-laboratories |access-date=2024-12-26 |website=Leave Russia}} The company's decision to maintain its presence in the region was criticized by organizations advocating for ethical corporate conduct during global conflicts.{{Cite web |title=Corporate Responses to Sanctions Against Russia |url=https://leave-russia.org/uk/servier-laboratories |access-date=2024-12-26 |website=Leave Russia}}

References

{{Reflist}}

External links

{{Portal|Medicine|France|Companies}}

  • {{Official website|https://servier.com/en/}}

{{Authority control}}

Category:Pharmaceutical companies established in 1954

Category:French companies established in 1954

Category:French brands

Category:Suresnes